hVIVO plc
5.45
GBX
-0.30
(-5.22%)
ISIN
GB00B9275X97
Return %
Stock
S&P 500
1Y
-22.14
14.20
3Y
-72.61
81.12
5Y
-74.05
68.34
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.Company Description
- CEO
- Yamin Mohammed Khan
- Full Time Employees
- 376
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 40 Bank Street London GL United Kingdom E14 5NR
- IPO Date
- Dec 14, 2012
- Website
- hvivo.com
- Similar Companies
- Business
- hVIVO plc is a specialist contract research organisation (CRO) focused on human challenge trials and clinical development solutions primarily in infectious and respiratory diseases. The company offers services including human challenge study models for respiratory syncytial virus (RSV), influenza (including the first influenza B human challenge trial), COVID-19, asthma, malaria, chronic obstructive pulmonary disease (COPD), and human metapneumovirus (hMPV). Additionally, hVIVO provides a comprehensive range of laboratory services via its hLAB platform, including virology, immunology, molecular assays, serology, PCR, infectivity assays, biomarker analysis, and clinical field trial logistics. hVIVO supports both preclinical and clinical drug development for vaccines and antivirals, serving pharmaceutical and biotech clients globally, with operations across the United Kingdom, Europe, and North America. Founded in 2011 and headquartered in London, United Kingdom, hVIVO has recently undergone significant strategic expansions. The company changed its name from Open Orphan plc to hVIVO plc in October 2022 to better reflect its specialist market position. In 2024 and early 2025, hVIVO substantially increased its laboratory capacity by tripling space at its Canary Wharf site, including commissioning a cutting-edge Containment Level 3 laboratory for high hazard pathogen work. It also expanded its assay portfolio to cover a broader range of pathogens, including Omicron variants, dengue, pertussis, and various influenza and rhinovirus strains. Furthermore, hVIVO launched the full suite of its hLAB services as standalone offerings to meet growing demand. A major recent corporate development includes the January 2025 acquisition of two clinical research units in Mannheim and Kiel, Germany, from CRS Clinical Research Services Management GmbH for €10 million. This acquisition strengthens hVIVO's European clinical trial footprint and extends its service offering to early-phase I and II trials in cardiometabolic, immunology/inflammation, renal, and hepatic impairment areas. The integration of CRS units enhances cross-selling opportunities, diversifies client base and revenue streams, and boosts the company's capacity for international clinical site capabilities and patient recruitment. The company forecasts continued revenue growth and margin improvement driven by expanded operations, a robust contract order book totaling approximately £67 million at the end of 2024, and a pipeline of new challenge models and services targeting £100 million revenue by 2028. hVIVO also emphasizes technology-driven efficiencies such as automation in its laboratories and has developed a live database accessible to clients for data transparency. Its strategic focus remains on pioneering human challenge trials, expanding laboratory services, and integrating acquired entities for broader clinical development solutions. In summary, hVIVO plc delivers specialized human challenge trial services, comprehensive virology and immunology laboratory testing, clinical trial logistics, and early-phase clinical trial operations across Europe and North America, leveraging recent expansions including the hLAB launch and the acquisition of CRS's German clinical research units to sustain rapid growth and broaden its therapeutic and geographic reach. The company is headquartered in London and was founded in 2011. Its client base mainly includes pharmaceutical and biotechnology companies seeking accelerated vaccine and antiviral product development. This description reflects hVIVO's current product and service portfolio, recent major corporate changes, market focus, and geographic operations as of late 2025.